

STEMSMART ACQUISITION COMPLETE

StemSmart Acquisition Highlights

- NSB has acquired 100% of the issued share capital of Isopogen WA (**Acquisition**), which holds or has the right to exploit the StemSmart™ patented Stem Cell technology (**StemSmart**).
- Cash on hand ~\$7.5million following the Placement to institutional, professional, and sophisticated investors.
- Robert McKenzie and Paul Fry appointed as non-executive directors, with Mr McKenzie as Chair effective from 27 June 2025. Marian Sturm to be appointed to the role of Chief Scientific Officer.
- StemSmart™ Mesenchymal Stem Cells (**MSC**) are derived from adult human donor bone marrow. The MSCs are isolated and grown in culture, before the patented StemSmart™ manufacturing process is applied to improve the cells' clinical efficacy.
- Special Access Program (**SAS Program**) in fistulising Crohn's disease **has now commenced**². The SAS Program will be the immediate focus of the Company. There is a strong need for alternative and effective treatments for Crohn's disease with fewer side effects.
- Early indications from a Phase 2 trial in refractory Crohn's disease suggest StemSmart™ MSC is potent, efficacious and safe¹. A Phase 2 trial of 18 patients with refractory Crohn's disease who received StemSmart™ MSC therapy demonstrated promising results, with the majority of patients experiencing clinical improvement and many, clinical remission¹.
- Previous Phase I clinical trial in adults with steroid-refractory GVHD³, and a series of children treated on compassionate grounds for steroid-refractory GVHD³ found the majority of adults and children responded to StemSmart™ with a complete or partial resolution of symptoms and improved survival.

StemSmart Key Addressable Markets³

- **Crohn's Disease:** Global market US\$13.8 billion by 2026;
- **Kidney Transplant:** Global market for organ transplant immuno-suppressants, increasing to US\$7.2 billion by 2030 (majority for renal);
- **Lung Disorders:** Global market US\$33 billion by 2034; and
- **GvHD:** Global market increasing to US\$5.31 billion in 2032.

NeuroScientific Biopharmaceuticals Ltd (**ASX:NSB**) or (**the Company** or **NSB**) is happy to advise that all conditions precedent have been satisfied (or waived), and the acquisition of the StemSmart™ patented Stem Cell technology (**StemSmart**) via its Acquisition of Isopogen WA Ltd (**Isopogen WA**) is complete.

For personal use only

Following completion of the Acquisition, the Company is pleased to advise of two new board appointments, Robert McKenzie as Non-Executive Chairman and Paul Fry as Non-Executive Director, effective from 27 June 2025. Further to the Appendix 3B dated 26 May 2025 and as part of their appointments, Mr McKenzie and Mr Fry will each receive a total of 5,000,000 unquoted options, exercisable at \$0.07 each and expiring 3 years from the date of issue. The Company also intends to enter into a consultancy arrangement with Mr Fry in respect to the provision of management services, charged at a day rate, to be conducted during a transitional period. Tony Keating and Christopher Ntoumenopoulos have resigned as executive director and non-executive chairman respectively.

Incoming Chairman, Robert McKenzie said:

“I’m pleased that NSB’s acquisition of Isopogen will allow our StemSmart™ technology to be progressed for the benefit of vulnerable patients with limited treatment options.

Our immediate focus will be on a special access clinical program in fistulising Crohn’s disease which is challenging to treat and where sustained healing has proven limited with standard therapies. Longer term our desire is to further clinical activities to progress the technology to achieve regulatory approval.

On behalf of the board, I’d like to thank outgoing directors Chris Ntoumenopoulos and Tony Keating for their services, and I look forward to working with Anton, Clarke and Paul during this exciting period for NSB.”

1. ASX Announcement 16 April 2025.
2. ASX Announcement 23 May 2025.
3. ASX Announcement 19 June 2025.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Chris Achurch (Company Secretary)

+61 8 6268 2641

For personal use only

Forward Looking Statements

This announcement may contain certain “forward-looking statements”. Forward looking statements can generally be identified by the use of forward-looking words such as, “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that plans of the directors and management of the Company will proceed as currently expected or will ultimately be successful. You are strongly cautioned not to place undue reliance on forward looking statements, including in respect of the financial or operating outlook for the Company. Except as required by law or any relevant listing rules of the ASX, the Company assumes no obligation to provide any additional or updated information or to update any forward looking statements, whether as a result of new information, future events or results, or otherwise. Nothing in this announcement will, under any circumstances (including by reason of this announcement remaining available and not being superseded or replaced by any other presentation or publication with respect to the Company, or the subject matter of this announcement), create an implication that there has been no change in the affairs of the Company since the date of this announcement.